CLADRIBINE Side Effects

7013418-8 | Grand Mal Convulsion
on Sep 09, 2010 Female patient from UNITED STATES , weighting 200.6 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), depression (What is depression?), headache (What is headache?), dysmenorrhoea and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: grand mal convulsion. Cladribine dosage: . During the same period patient was treated with REBIF (View Rebif Review and Rebif Label ), WELLBUTRIN (View Wellbutrin Review and Wellbutrin Label ), HYDROCODONE + ACCETAMINOPHEN (View Hydrocodone + Accetaminophen Review and Hydrocodone + Accetaminophen Label ), MIDOL (OTC) (View Midol (otc) Review and Midol (otc) Label ). Patient was hospitalized.

6977926-8 | Neutrophil Count Decreased
Patient was taking Cladribine (View Usage). Patient had the following side effects: neutrophil count decreased on Sep 07, 2010 from POLAND Additional patient health information: Female patient , weighting 125.7 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?), contraception, mood altered and. Cladribine dosage: . During the same period patient was treated with REBIF (View Rebif Review and Rebif Label ), NORDETTE 28 (View Nordette-28 Review and Nordette-28 Label ), FLUOXEMERCK 20 MG (View Fluoxemerck 20 Mg Review and Fluoxemerck 20 Mg Label ).

6977924-4 | Hypoxia, Pneumonia
Adverse event was reported on Aug 30, 2010 by a Female patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?), constipation (What is constipation?) and. Location: UNITED STATES , weighting 110.2 lb, After Cladribine was administered, patient had the following side effects: hypoxia, pneumonia (What is pneumonia?). During the same period patient was treated with REBIF (View Rebif Review and Rebif Label ), COLACE (View Colace Review and Colace Label ). Patient was hospitalized.

6973160-6 | Nausea, Neutropenia, Systemic Mastocytosis
on Aug 31, 2010 Male patient from AUSTRIA , 42 years of age, was diagnosed with systemic mastocytosis and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: nausea (What is nausea?), neutropenia, systemic mastocytosis. Cladribine dosage: 2-hour Infusion On 5 Consecutive Days. During the same period patient was treated with HISTAMINE RECEPTOR ANTAGONISTS (View Histamine Receptor Antagonists Review and Histamine Receptor Antagonists Label ), GLUCOCORTICOSTEROIDS (View Glucocorticosteroids Review and Glucocorticosteroids Label ).


6973135-7 | Neutropenia, Systemic Mastocytosis, Therapeutic Response Decreased, Thrombocytopenia
on Aug 31, 2010 Male patient from AUSTRIA , 21 years of age, was diagnosed with systemic mastocytosis and was treated with Cladribine (View Usage). Patient had the following side effects: neutropenia, systemic mastocytosis, therapeutic response decreased, thrombocytopenia. Cladribine dosage: 2-hour Infusion On 5 Consecutive Days. During the same period patient was treated with HISTAMINE RECEPTOR ANTAGONISTS (View Histamine Receptor Antagonists Review and Histamine Receptor Antagonists Label ), IMATINIB (View Imatinib Review and Imatinib Label ), GLUCOCORTICOSTEROIDS (View Glucocorticosteroids Review and Glucocorticosteroids Label ).

6973134-5 | Anaemia, Neutropenia, Systemic Mastocytosis, Thrombocytopenia
Patient was taking Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: anaemia, neutropenia, systemic mastocytosis, thrombocytopenia on Aug 31, 2010 from AUSTRIA Additional patient health information: Male patient , 59 years of age, was diagnosed with systemic mastocytosis and. Cladribine dosage: 2-hour Infusion On 5 Consecutive Days. During the same period patient was treated with ANTIHISTAMINE (View Antihistamine Review and Antihistamine Label ), GLUCOCORTICOSTEROIDS (View Glucocorticosteroids Review and Glucocorticosteroids Label ).

6973133-3 | Anaemia, Systemic Mastocytosis, Thrombocytopenia
Adverse event was reported on Aug 31, 2010 by a Male patient taking Cladribine (View Usage) (Dosage: 2-hour Infusion, On 5 Consecutive Days) was diagnosed with systemic mastocytosis and. Location: AUSTRIA , 71 years of age, Patient experienced the following unwanted or unexpected effects: anaemia, systemic mastocytosis, thrombocytopenia. During the same period patient was treated with GLUCOCORTICOSTEROIDS (View Glucocorticosteroids Review and Glucocorticosteroids Label ), HISTAMINE RECEPTOR ANTAGONISTS (View Histamine Receptor Antagonists Review and Histamine Receptor Antagonists Label ).

6861135-7 | Deep Vein Thrombosis, Papilloedema, Pulmonary Embolism, Sepsis, Thrombocytopenia, Varicella
on Jul 15, 2010 Male patient from UNITED STATES , weighting 229.1 lb, was diagnosed with mantle cell lymphoma and was treated with Cladribine (View Usage). Patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), papilloedema, pulmonary embolism (What is pulmonary embolism?), sepsis (What is sepsis?), thrombocytopenia, varicella. Cladribine dosage: . During the same period patient was treated with VELCADE (View Velcade Review and Velcade Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized.

6816124-5 | Constipation
on Jul 02, 2010 Male patient from UNITED STATES , 83 years of age, weighting 156.7 lb, was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: constipation (What is constipation?). Cladribine dosage: Iv. Patient was hospitalized.

6784127-5 | Confusional State, Fatigue, Pyrexia, Rash
Patient was taking Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: confusional state, fatigue, pyrexia, rash (What is rash?) on Jun 15, 2010 from UNITED STATES Additional patient health information: Female patient , 61 years of age, was diagnosed with castleman's disease and. Cladribine dosage: . Patient was hospitalized.

6714971-1 | Enterobacter Sepsis, Febrile Neutropenia, Hypotension, Incorrect Dose Administered
Adverse event was reported on Apr 27, 2010 by a Female patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , child 8 years of age, Patient had the following side effects: enterobacter sepsis, febrile neutropenia, hypotension, incorrect dose administered. During the same period patient was treated with TOPOTECAN (View Topotecan Review and Topotecan Label ).

6714970-X | Acute Myeloid Leukaemia, Febrile Neutropenia, Incorrect Dose Administered, Malignant Neoplasm Progression, Pleural Effusion, Renal Failure, Respiratory Failure
on Apr 27, 2010 Female patient from UNITED STATES , 15 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: acute myeloid leukaemia, febrile neutropenia, incorrect dose administered, malignant neoplasm progression, pleural effusion, renal failure, respiratory failure. Cladribine dosage: Given Intravenously Over 3 Hours. During the same period patient was treated with TOPOTECAN (Intravenously Over 30 Minutes, Starting 8 Hours After Initiation Of Cladribine) (View Topotecan Review and Topotecan Label ).

6697033-1 | Deep Vein Thrombosis, Papilloedema, Pulmonary Embolism, Sepsis, Thrombocytopenia, Varicella
on Apr 13, 2010 Male patient from UNITED STATES , weighting 229.1 lb, was diagnosed with mantle cell lymphoma and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: deep vein thrombosis (What is deep vein thrombosis?), papilloedema, pulmonary embolism (What is pulmonary embolism?), sepsis (What is sepsis?), thrombocytopenia, varicella. Cladribine dosage: . During the same period patient was treated with VELCADE (View Velcade Review and Velcade Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized.

6633966-X | Hypovolaemic Shock, Small Intestinal Haemorrhage
Patient was taking Cladribine (View Usage). Patient had the following side effects: hypovolaemic shock, small intestinal haemorrhage on Mar 05, 2010 from POLAND Additional patient health information: Male patient , 43 years of age, was diagnosed with acute myeloid leukaemia, prophylaxis against graft versus host disease and. Cladribine dosage: . During the same period patient was treated with DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

6601000-3 | Azotaemia, C-reactive Protein Increased, Decreased Appetite, Gamma-glutamyltransferase Increased, Hepatic Function Abnormal, Hyperbilirubinaemia, Hyperhidrosis, Hyperkalaemia, Hypoalbuminaemia
Adverse event was reported on Feb 16, 2010 by a Male patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with hairy cell leukaemia, prophylaxis, infection prophylaxis, rash (What is rash?) and. Location: JAPAN , weighting 145.5 lb, After Cladribine was administered, patient had the following side effects: azotaemia, c-reactive protein increased, decreased appetite, gamma-glutamyltransferase increased, hepatic function abnormal, hyperbilirubinaemia, hyperhidrosis, hyperkalaemia, hypoalbuminaemia. During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), CIPROFLOXACIN HYDROCHLORIDE (View Ciprofloxacin Hydrochloride Review and Ciprofloxacin Hydrochloride Label ), BAKTAR (View Baktar Review and Baktar Label ), MODACIN (View Modacin Review and Modacin Label ), GENTAMICIN (View Gentamicin Review and Gentamicin Label ), IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (View Immune Globulin Intravenous (human) Review and Immune Globulin Intravenous (human) Label ), ALLELOCK (View Allelock Review and Allelock Label ).

6573098-2 | Chronic Obstructive Pulmonary Disease, Oropharyngeal Pain, Pancytopenia
on Jan 28, 2010 Male patient from UNITED STATES , weighting 119.0 lb, was diagnosed with lymphoplasmacytoid lymphoma/immunocytoma and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: chronic obstructive pulmonary disease, oropharyngeal pain, pancytopenia. Cladribine dosage: . During the same period patient was treated with VELCADE (View Velcade Review and Velcade Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized.

6368604-7 | Neuroendocrine Carcinoma Of The Skin
on Sep 21, 2009 Female patient from POLAND , 51 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Cladribine (View Usage). Patient had the following side effects: neuroendocrine carcinoma of the skin. Cladribine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), VINCRISTINE (Dose Not Specified) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (Dose Not Specified) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (Dose Not Specified) (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (Day 1 Of A 28-day Cycle) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6199493-1 | Aplastic Anaemia, Bacteraemia, Neutropenia, Pancytopenia
Patient was taking Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: aplastic anaemia, bacteraemia, neutropenia, pancytopenia on May 20, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 19.84 lb, was diagnosed with histiocytosis and. Cladribine dosage: 17 Mg Kg/kg/dose X 5 Days Q 3wks 2 Iv 5 Mg/m2/dose X 5 Days Q 3 Wks 9 Iv. Patient was hospitalized.

6147619-8 | Extravasation
Adverse event was reported on Feb 25, 2009 by a Male patient taking Cladribine (View Usage) (Dosage: 5 Day Regimen Iv) was diagnosed with hairy cell leukaemia and. Location: UNITED STATES , 83 years of age, weighting 186.0 lb, Patient experienced the following unwanted or unexpected effects: extravasation.

6092733-9 | Lymphoma
on Jul 22, 2008 Female patient from FRANCE , 73 years of age, was diagnosed with immunoblastic lymphoma and was treated with Cladribine (View Usage). Patient had the following side effects: lymphoma (What is lymphoma?). Cladribine dosage: .

6022270-9 | Cardiomyopathy, Ejection Fraction Decreased, Ventricular Hypokinesia
on Dec 29, 2008 Female patient from GREECE , 30 years of age, weighting 149.9 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: cardiomyopathy (What is cardiomyopathy?), ejection fraction decreased, ventricular hypokinesia. Cladribine dosage: . Patient was hospitalized.

5948601-3 | Decreased Activity, Decreased Appetite, Disorientation, Disseminated Cytomegaloviral Infection, Hypoalbuminaemia, Pancytopenia, Pyrexia, Renal Impairment, Respiratory Failure
Patient was taking Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: decreased activity, decreased appetite, disorientation, disseminated cytomegaloviral infection, hypoalbuminaemia, pancytopenia, pyrexia, renal impairment, respiratory failure on Nov 05, 2008 from JAPAN Additional patient health information: Male patient , weighting 97.00 lb, was diagnosed with mantle cell lymphoma, infection susceptibility increased, prophylaxis and. Cladribine dosage: Cycle 3. During the same period patient was treated with NOVANTRONE (Cycle 3) (View Novantrone Review and Novantrone Label ), COTRIM (View Cotrim Review and Cotrim Label ), RITUXAN (Cycle 3) (View Rituxan Review and Rituxan Label ).

5853657-2 | Cardiomyopathy, Ejection Fraction Decreased, Ventricular Hypokinesia
Adverse event was reported on Aug 12, 2008 by a Female patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: GREECE , 30 years of age, weighting 149.9 lb, Patient had the following side effects: cardiomyopathy (What is cardiomyopathy?), ejection fraction decreased, ventricular hypokinesia. Patient was hospitalized.

5841208-8 | Disseminated Intravascular Coagulation, Hyperbilirubinaemia, Hypersensitivity, Hypotension, Pyrexia, Rash, Renal Impairment, Swelling Face, Thrombocytopenia
on Aug 07, 2008 Male patient from UNITED KINGDOM , 67 years of age, weighting 143.3 lb, was diagnosed with hairy cell leukaemia, hypertension, infection prophylaxis, hyperlipidaemia and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: disseminated intravascular coagulation, hyperbilirubinaemia, hypersensitivity, hypotension, pyrexia, rash (What is rash?), renal impairment, swelling face, thrombocytopenia. Cladribine dosage: . During the same period patient was treated with ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), BENDROFLUMETHIAZIDE (View Bendroflumethiazide Review and Bendroflumethiazide Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

5824019-9 | Lymphoma
on Jul 22, 2008 Female patient from FRANCE , 73 years of age, was diagnosed with immunoblastic lymphoma and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: lymphoma (What is lymphoma?). Cladribine dosage: .

5696515-9 | Gingival Bleeding, Pyrexia
Patient was taking Cladribine (View Usage). Patient had the following side effects: gingival bleeding, pyrexia on Mar 28, 2008 from BRAZIL Additional patient health information: Male patient , 34 years of age, was diagnosed with hairy cell leukaemia and. Cladribine dosage: . Patient was hospitalized.

5674320-7 | Neutropenia
Adverse event was reported on Dec 20, 2007 by a Male patient taking Cladribine (View Usage) (Dosage: 0.09 Mg/kg Daily For A 7-day Pre) was diagnosed with hairy cell leukaemia and. Location: UNITED STATES , 41 years of age, weighting 209.4 lb, After Cladribine was administered, patient had the following side effects: neutropenia. During the same period patient was treated with ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), XANAX (View Xanax Review and Xanax Label ), DECADRON (View Decadron Review and Decadron Label ), COLACE (View Colace Review and Colace Label ), HEPARIN LOCK FLUSH (View Heparin Lock-flush Review and Heparin Lock-flush Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ), ATIVAN (View Ativan Review and Ativan Label ).

5568099-7 | Eosinophilia, Neutrophil Count Decreased, Pyrexia
on Dec 13, 2007 Female patient from JAPAN , 78 years of age, was diagnosed with hairy cell leukaemia, antifungal prophylaxis and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: eosinophilia, neutrophil count decreased, pyrexia. Cladribine dosage: For 7 Days. During the same period patient was treated with ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), TRIMETHOPRIM (View Trimethoprim Review and Trimethoprim Label ). Patient was hospitalized.

5566321-4 | Eosinophilia, Neutrophil Count Decreased, Pyrexia
on Dec 06, 2007 Female patient from JAPAN , 78 years of age, was diagnosed with hairy cell leukaemia, antifungal prophylaxis and was treated with Cladribine (View Usage). Patient had the following side effects: eosinophilia, neutrophil count decreased, pyrexia. Cladribine dosage: For 7 Days. During the same period patient was treated with ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), TRIMETHOPRIM (View Trimethoprim Review and Trimethoprim Label ). Patient was hospitalized.

5315720-4 | Pancytopenia
Patient was taking Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: pancytopenia on Apr 30, 2007 from UNITED STATES Additional patient health information: Female patient , 39 years of age, was diagnosed with hairy cell leukaemia and. Cladribine dosage: 0.09mg/kg Iv. Patient was hospitalized.

5268594-4 | Extravasation, Injection Site Reaction
Adverse event was reported on Mar 15, 2007 by a Male patient taking Cladribine (View Usage) (Dosage: 8.8 Mg/day Iv In 500 Ml Ns Continuous Infusion X 7 Days) was diagnosed with hairy cell leukaemia and. Location: UNITED STATES , 77 years of age, weighting 217.0 lb, Patient experienced the following unwanted or unexpected effects: extravasation, injection site reaction.

5262612-5 | Hepatitis Acute
on Feb 19, 2007 Female patient from TUNISIA , 56 years of age, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Cladribine (View Usage). Patient had the following side effects: hepatitis acute. Cladribine dosage: (0.875 Mg/kg, 7 In 1 Cycle, Oral. Patient was hospitalized.

5192269-3 | Hepatic Enzyme Increased, Metastases To Bone, Metastases To Liver, Oesophageal Carcinoma
on Dec 22, 2006 Male patient from UNITED STATES , weighting 262.0 lb, was diagnosed with multiple sclerosis (What is multiple sclerosis?) and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: hepatic enzyme increased, metastases to bone, metastases to liver, oesophageal carcinoma. Cladribine dosage: . During the same period patient was treated with NOVANTRONE (View Novantrone Review and Novantrone Label ), COPAXONE (View Copaxone Review and Copaxone Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMITRIPTYLINE HCL (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ). Patient was hospitalized.

5115453-3 | Diplopia, Erythema, Eye Irritation, Headache, Hypersensitivity, Mouth Ulceration, Mucosal Ulceration, Skin Reaction, Swelling Face
Patient was taking Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: diplopia, erythema, eye irritation, headache (What is headache?), hypersensitivity, mouth ulceration, mucosal ulceration, skin reaction, swelling face on Sep 07, 2006 from GERMANY Additional patient health information: Female patient , 19 years of age, was diagnosed with relapsing-remitting multiple sclerosis and. Cladribine dosage: 1 Dosage Forms (0.875 Mg/kg, 5 In 1 Cycle) Oral. During the same period patient was treated with IMPLANON (View Implanon Review and Implanon Label ).

5082728-6 | Cytokine Storm, Dyspnoea, Febrile Neutropenia, Hypotension, Thrombophlebitis Superficial
Adverse event was reported on Aug 16, 2006 by a Male patient taking Cladribine (View Usage) (Dosage: Iv) was diagnosed with hairy cell leukaemia, febrile neutropenia and. Location: UNITED STATES , 64 years of age, weighting 203.0 lb, Patient had the following side effects: cytokine storm, dyspnoea, febrile neutropenia, hypotension, thrombophlebitis superficial. During the same period patient was treated with ZOSYN (Iv ~1-2 Days) (View Zosyn Review and Zosyn Label ), ADVICOR (View Advicor Review and Advicor Label ), PROZAC (View Prozac Review and Prozac Label ). Patient was hospitalized.

4967309-4 | Diffuse Large B-cell Lymphoma, Listeriosis, Tuberculosis
on Mar 27, 2006 Male patient from AUSTRALIA , 77 years of age, was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: diffuse large b-cell lymphoma, listeriosis, tuberculosis (What is tuberculosis?). Cladribine dosage: .

4967308-2 | Hypoxia, Lobar Pneumonia, Lung Infiltration, Neutropenic Sepsis, Waldenstrom's Macroglobulinaemia Refractory
on Mar 27, 2006 Female patient from AUSTRALIA , 74 years of age, was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: hypoxia, lobar pneumonia, lung infiltration, neutropenic sepsis, waldenstrom's macroglobulinaemia refractory. Cladribine dosage: .

4964337-X | Chromosomal Deletion, Diverticular Perforation, Fungal Infection, Herpes Zoster, Operative Haemorrhage, Pancytopenia, Pemphigus, Pseudomonas Infection, Staphylococcal Impetigo
Patient was taking Cladribine (View Usage). Patient had the following side effects: chromosomal deletion, diverticular perforation, fungal infection (What is fungal infection?), herpes zoster, operative haemorrhage, pancytopenia, pemphigus (What is pemphigus?), pseudomonas infection, staphylococcal impetigo on Mar 29, 2006 from UNITED STATES Additional patient health information: Male patient , 60 years of age, . Cladribine dosage: . Patient was hospitalized.

4957705-3 | Hepatic Enzyme Increased, Metastases To Liver, Oesophageal Carcinoma
Adverse event was reported on Mar 17, 2006 by a Male patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with multiple sclerosis (What is multiple sclerosis?) and. Location: UNITED STATES , 56 years of age, weighting 262.0 lb, After Cladribine was administered, patient had the following side effects: hepatic enzyme increased, metastases to liver, oesophageal carcinoma. During the same period patient was treated with NOVANTRONE (View Novantrone Review and Novantrone Label ), COPAXONE (View Copaxone Review and Copaxone Label ). Patient was hospitalized.

4932886-6 | Fall, Femur Fracture, Hairy Cell Leukaemia, Pancytopenia, Sepsis
on Feb 20, 2006 Female patient from JAPAN , weighting 93.26 lb, was diagnosed with hairy cell leukaemia, sepsis (What is sepsis?) and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: fall (What is fall?), femur fracture, hairy cell leukaemia, pancytopenia, sepsis (What is sepsis?). Cladribine dosage: . During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CEFOZOPRAN HYDROCHLORIDE (View Cefozopran Hydrochloride Review and Cefozopran Hydrochloride Label ). Patient was hospitalized.

4890875-4 | Myelodysplastic Syndrome
on Jan 13, 2006 Male patient from IRELAND , 36 years of age, was treated with Cladribine (View Usage). Patient had the following side effects: myelodysplastic syndrome. Cladribine dosage: .

4890874-2 | Neuroendocrine Carcinoma Of The Skin
Patient was taking Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: neuroendocrine carcinoma of the skin on Jan 13, 2006 from POLAND Additional patient health information: Female patient , 51 years of age, . Cladribine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), VINCRISTINE (Dose Not Specified) (View Vincristine Review and Vincristine Label ), DOXORUBICIN (Dose Not Specified) (View Doxorubicin Review and Doxorubicin Label ), PREDNISONE (Dose Not Specified) (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (Day 1 Of A 28-day Cycle) (View Cyclophosphamide Review and Cyclophosphamide Label ).

4797077-0 | Dialysis, Nephritis Allergic, Nephritis Interstitial, Pyrexia, Rash, Renal Failure Acute
Adverse event was reported on Oct 11, 2005 by a Female patient taking Cladribine (View Usage) (Dosage: 6 Mg Daily Iv) was diagnosed with hairy cell leukaemia, sepsis (What is sepsis?) and. Location: UNITED STATES , 84 years of age, weighting 154.3 lb, Patient experienced the following unwanted or unexpected effects: dialysis (What is dialysis?), nephritis allergic, nephritis interstitial, pyrexia, rash (What is rash?), renal failure acute. During the same period patient was treated with CEFEPIME (2 Gram Every 8 Hours Iv) (View Cefepime Review and Cefepime Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), INDAPAMIDE (View Indapamide Review and Indapamide Label ), ASPIRIN (View Aspirin Review and Aspirin Label ).

4723719-1 | Cystitis Haemorrhagic, Hydronephrosis, Pancytopenia, Pyelonephritis
on Jul 11, 2005 Female patient from JAPAN , 26 years of age, weighting 99.65 lb, was diagnosed with b-cell lymphoma and was treated with Cladribine (View Usage). Patient had the following side effects: cystitis haemorrhagic, hydronephrosis, pancytopenia, pyelonephritis. Cladribine dosage: Cycle 6.

4723718-X | Herpes Zoster, Myelodysplastic Syndrome
on Jul 11, 2005 Male patient from JAPAN , 71 years of age, weighting 138.9 lb, was diagnosed with mantle cell lymphoma and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: herpes zoster, myelodysplastic syndrome. Cladribine dosage: . During the same period patient was treated with PSL (View Psl Review and Psl Label ).

4723717-8 | Myelodysplastic Syndrome, Refractory Anaemia
Patient was taking Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: myelodysplastic syndrome, refractory anaemia on Jul 11, 2005 from JAPAN Additional patient health information: Female patient , 41 years of age, weighting 112.4 lb, was diagnosed with mycosis fungoides and. Cladribine dosage: .

4723716-6 | Myelodysplastic Syndrome
Adverse event was reported on Jul 11, 2005 by a Male patient taking Cladribine (View Usage) (Dosage: ) was diagnosed with b-cell lymphoma and. Location: JAPAN , 49 years of age, weighting 140.7 lb, Patient had the following side effects: myelodysplastic syndrome. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

4723715-4 | Heart Rate Decreased, Ventricular Extrasystoles
on Jul 11, 2005 Male patient from JAPAN , 56 years of age, weighting 176.4 lb, was diagnosed with b-cell lymphoma and was treated with Cladribine (View Usage). After Cladribine was administered, patient had the following side effects: heart rate decreased, ventricular extrasystoles. Cladribine dosage: .

4723714-2 | Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Refractory, Gastrointestinal Haemorrhage, Herpes Simplex, Malignant Neoplasm Progression, Pancytopenia
on Jul 11, 2005 Male patient from JAPAN , 32 years of age, weighting 129.2 lb, was diagnosed with mycosis fungoides, b-cell lymphoma and was treated with Cladribine (View Usage). Patient experienced the following unwanted or unexpected effects: follicle centre lymphoma, follicular grade i, ii, iii refractory, gastrointestinal haemorrhage, herpes simplex (What is herpes simplex?), malignant neoplasm progression, pancytopenia. Cladribine dosage: .

4723713-0 | Aspergillosis, Cerebral Haemorrhage, Disseminated Intravascular Coagulation, Interstitial Lung Disease, Malaise, Pancytopenia, Performance Status Decreased
Patient was taking Cladribine (View Usage). Patient had the following side effects: aspergillosis, cerebral haemorrhage, disseminated intravascular coagulation, interstitial lung disease, malaise, pancytopenia, performance status decreased on Jul 11, 2005 from JAPAN Additional patient health information: Male patient , 68 years of age, weighting 118.6 lb, was diagnosed with b-cell lymphoma and. Cladribine dosage: Cycle 5 (administered For 7 Consecutive Days).